SG11202102490TA - Tyk2 kinase inhibitors - Google Patents
Tyk2 kinase inhibitorsInfo
- Publication number
- SG11202102490TA SG11202102490TA SG11202102490TA SG11202102490TA SG11202102490TA SG 11202102490T A SG11202102490T A SG 11202102490TA SG 11202102490T A SG11202102490T A SG 11202102490TA SG 11202102490T A SG11202102490T A SG 11202102490TA SG 11202102490T A SG11202102490T A SG 11202102490TA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitors
- tyk2 kinase
- tyk2
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1816369.1A GB201816369D0 (en) | 2018-10-08 | 2018-10-08 | Pharmaceutical compounds |
| PCT/EP2019/077118 WO2020074461A1 (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102490TA true SG11202102490TA (en) | 2021-04-29 |
Family
ID=64397425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102490TA SG11202102490TA (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210387981A1 (en) |
| EP (1) | EP3864009A1 (en) |
| JP (1) | JP7383030B2 (en) |
| KR (1) | KR20210076036A (en) |
| CN (1) | CN113056456B (en) |
| AU (1) | AU2019359320B2 (en) |
| BR (1) | BR112021006424A2 (en) |
| CA (1) | CA3111049A1 (en) |
| GB (1) | GB201816369D0 (en) |
| IL (1) | IL281599A (en) |
| MX (1) | MX2021003929A (en) |
| SG (1) | SG11202102490TA (en) |
| WO (1) | WO2020074461A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005114D0 (en) * | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0709031D0 (en) * | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| CA2690141A1 (en) | 2007-06-20 | 2008-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CA2719847A1 (en) | 2008-04-21 | 2010-01-28 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CA2727928A1 (en) | 2008-06-18 | 2009-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| JP2011527680A (en) | 2008-07-09 | 2011-11-04 | メルク・シャープ・エンド・ドーム・コーポレイション | JANUS kinase inhibitors |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| CN102869359A (en) | 2010-03-17 | 2013-01-09 | 弗·哈夫曼-拉罗切有限公司 | Imidazopyridine compounds, compositions and methods of use |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| EP2634185B1 (en) * | 2012-03-02 | 2016-01-13 | Sareum Limited | TYK2 kinase inhibitors |
| KR101202026B1 (en) | 2012-07-03 | 2012-11-16 | 민호현 | Method for manufacturing loess stone-planting |
| HRP20220766T1 (en) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| JP6239118B2 (en) | 2013-09-03 | 2017-11-29 | サリウム リミテッド | Pharmaceutical compounds |
| NO2721710T3 (en) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
-
2018
- 2018-10-08 GB GBGB1816369.1A patent/GB201816369D0/en not_active Ceased
-
2019
- 2019-10-07 JP JP2021543577A patent/JP7383030B2/en active Active
- 2019-10-07 WO PCT/EP2019/077118 patent/WO2020074461A1/en active Application Filing
- 2019-10-07 KR KR1020217013504A patent/KR20210076036A/en unknown
- 2019-10-07 CN CN201980066166.4A patent/CN113056456B/en active Active
- 2019-10-07 SG SG11202102490TA patent/SG11202102490TA/en unknown
- 2019-10-07 BR BR112021006424A patent/BR112021006424A2/en unknown
- 2019-10-07 CA CA3111049A patent/CA3111049A1/en active Pending
- 2019-10-07 US US17/283,151 patent/US20210387981A1/en active Pending
- 2019-10-07 EP EP19794095.0A patent/EP3864009A1/en active Pending
- 2019-10-07 AU AU2019359320A patent/AU2019359320B2/en active Active
- 2019-10-07 MX MX2021003929A patent/MX2021003929A/en unknown
-
2021
- 2021-03-17 IL IL281599A patent/IL281599A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113056456B (en) | 2023-06-13 |
| GB201816369D0 (en) | 2018-11-28 |
| MX2021003929A (en) | 2021-06-04 |
| IL281599A (en) | 2021-05-31 |
| AU2019359320B2 (en) | 2024-04-04 |
| US20210387981A1 (en) | 2021-12-16 |
| CA3111049A1 (en) | 2020-04-16 |
| EP3864009A1 (en) | 2021-08-18 |
| BR112021006424A2 (en) | 2021-07-06 |
| CN113056456A (en) | 2021-06-29 |
| WO2020074461A1 (en) | 2020-04-16 |
| KR20210076036A (en) | 2021-06-23 |
| JP7383030B2 (en) | 2023-11-17 |
| JP2022514799A (en) | 2022-02-15 |
| AU2019359320A1 (en) | 2021-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| IL289534A (en) | Parp1 inhibitors | |
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| ZA201901034B (en) | Macrocycle kinase inhibitors | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL280593A (en) | Pyrrolopyrimidine itk inhibitors | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| IL283409A (en) | Tyk2 inhibitors and uses thereof | |
| IL291453A (en) | Dosage forms for tyk2 inhibitors | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| ZA201808238B (en) | Certain protein kinase inhibitors | |
| IL281599A (en) | Tyk2 kinase inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL282941A (en) | Rock kinase inhibitors | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201812462D0 (en) | Inhibitors | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| AU2017904208A0 (en) | Novel kinase inhibitors i | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors |